Pharmaceuticals

An Alabama firm's key regulatory filing for a critical drug component could accelerate the development of cheaper cancer supportive care biosimilars.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

Amid fierce competition, Triangle Insights Group hires a seasoned expert to guide clients through the complex world of drug pricing and market access.

In the quest to drug the 'undruggable,' Erasca consolidates worldwide control of its promising pan-RAS inhibitor, setting the stage for a global showdown.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

Atlanta lawyer Anne Tyler Hall lands on Inc.'s prestigious list for saving companies millions and mastering complex employee benefits law.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

Assets of pioneering engineering firm Xytel Corp. go to auction after its closure, offering rare deals on high-demand industrial equipment.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Paperpal's new HIPAA-ready AI platform for life sciences offers secure data handling, aiming to accelerate research while ensuring regulatory compliance.

Alzheon's pill ALZ-801 shows promise in early AD patients with high genetic risk, offering a potential path that avoids the brain swelling seen in IV drugs.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

A global consortium pioneers new drugs designed specifically for children, moving away from harsh adult treatments for aggressive pediatric cancers.

ViruSure's new GMP-validated test using Oxford Nanopore sequencing promises to slash drug safety testing times, boosting supply chain resilience.

Telehealth firm Direct Meds offers cheap GLP-1 drugs, but an FDA warning for "false claims" and the end of drug shortages cast a long shadow on its model.

After 15 years without new therapies, Tonix Pharma's TONMYA enters the fibromyalgia market with a unique sublingual drug and an ambitious commercial plan.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.